منابع مشابه
The future of treatment for antiphospholipid syndrome
Antiphospholipid syndrome (APS) is an auto immune multisystemic disorder in which patients develop recurrent thrombosis and preg nancy morbidity in the presence of antiphospho lipid antibodies (aPL), including anticardiolipin, antib2 glycoprotein I (antib 2 GPI) and lupus anticoagulant [1,2]. Secondary APS is the desig nation given to patients who have the disorder as well as a related co...
متن کاملGuidelines for the treatment of antiphospholipid syndrome.
The antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial and venous thrombosis, gestational morbidity and presence of elevated and persistently positive serum titers of antiphospholipid antibodies. The treatment of APS is still controversial, because any therapeutic decision potentially faces the risk of an insufficient or excessive antithrombotic coverage ...
متن کاملTreatment of antiphospholipid antibody syndrome
Antiphospholipid antibody syndrome (APS) is a systemic autoimmune disease with thrombotic predilection resulting in vascular thrombotic events and obstetric complications. Management of APS focuses on anticoagulation; however, despite the solid evidence suggesting that this is the best treatment option available, a lot of debate persists regarding the intensity and duration of anticoagulation n...
متن کاملStroke and antiphospholipid syndrome: the treatment debate.
Antiphospholipid syndrome (APS) is one of the most frequent acquired thrombophilias. Thromboses can be at both the venous and arterial level, are usually recurrent and frequently affect cerebral circulation. Although it is difficult to predict which patients with antiphospholipid antibodies (aPL) will develop thrombosis, once a thrombotic event has taken place, secondary prevention is mandatory...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Journal of Thrombosis and Hemostasis
سال: 2008
ISSN: 1880-8808,0915-7441
DOI: 10.2491/jjsth.19.333